Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00226967 · ClinicalTrials.gov registry record

Stress, Diurnal Cortisol, and Breast Cancer Survival

A clinical trial of Breast Cancer, sponsored by Stanford University.

Completed
Registry status
115
Enrollment target
1
Study location

NCT00226967: Completed study of Breast Cancer, sponsored by Stanford University.

NCT00226967 is a study of Breast Cancer that has completed, run by Stanford University. The registered enrollment target is 115 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00226967, a study of Breast Cancer, has completed, sponsored by Stanford University.

COMPLETED
Registry status
115 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn about the effects of stress on hormones, the relationship between these hormones and cancer progression.

Conditions Studied

Interventions

  • DRUG Sandostatin

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2002-09-08
Est. Completion 2005-12

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT00226967

The ClinicalTrials.gov registry entry for NCT00226967 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sandostatin is the first listed.

NCT00226967 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00226967 about?

NCT00226967 is a clinical study titled "Stress, Diurnal Cortisol, and Breast Cancer Survival". The purpose of this study is to learn about the effects of stress on hormones, the relationship between these hormones and cancer progression.

What is the current status of trial NCT00226967?

This trial is currently completed. The enrollment target is 115 participants. The study started on 2002-09-08. Estimated completion is 2005-12.

What conditions does trial NCT00226967 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00226967?

The interventions under investigation include: Sandostatin (DRUG).

Who is sponsoring clinical trial NCT00226967?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00226967 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.